Sponsored: This article was produced by Being Patient in partnership with Charter Research. More information on Alzheimer’s clinical trials can be found on the…
Some drug developers have put stock in the cholinergic hypothesis, developing a type of medication known as cholinesterase inhibitors. While Alzheimer’s still has no…
Researchers at the Salk Institute for Biological Studies have reported that a drug candidate called CMS121 has successfully halted and possibly reversed memory loss in…
Alzheimer’s Disease takes hundreds of thousands of lives every year, affecting 47 million people worldwide. But so far, no amount of urgency, nor billions…
About seven out of ten cases of Alzheimer’s are accompanied by symptoms of agitation and aggression. This could mean pacing, restlessness, shouting and screaming,…
Targeting beta-amyloid protein before symptoms of cognitive decline or Alzheimer’s appear is the goal of one trial out of the National Institute on Aging…
Whether it’s diet, exercise or air pollution, researchers are constantly investigating lifestyle and environmental factors that may play a role in the progression or…
The U.S. Food and Drug Administration (FDA) has approved a re-dosing study for patients formerly enrolled in Biogen’s phase three clinical trials of its…
In a new study, scientists have tested an experimental drug in mice that may hold promise for future Alzheimer’s treatments. The drug involves a…
Biogen has agreed to buy an experimental Alzheimer’s and Parkinson’s treatment from Pfizer, the company announced Monday. In the agreed deal, Biogen will pay…
Chinese officials announced conditional approval to a seaweed-based drug in November. Now, it’s available on the Chinese market. Oligomannate is the first drug to…
As research into a cure — or at least treatment — for Alzheimer’s continues, scientists are looking beyond the pathways of targeting tau or…
Last week, Biogen announced that its Alzheimer’s drug aducanumab was effective in combating Alzheimer’s disease, and that it would be reviving a trial cancelled…
When biotechnology company Biogen announced the cancellation of the trial for their Alzheimer’s drug aducanumab, nearly 3,500 trial participants were left in limbo. Now,…
SAN DIEGO — The scientific data was virtually unreadable, the explanations often too complex for the layman or woman to understand. But there was…